Filing Details
- Accession Number:
- 0001415889-25-008141
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-14 17:20:05
- Reporting Period:
- 2025-03-12
- Filing Date:
- 2025-03-14
- Accepted Time:
- 2025-03-14 17:20:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1070081 | Ptc Therapeutics Inc. | PTCT | Pharmaceutical Preparations (2834) | 043416587 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578852 | Elliott Mark Boulding | C/O Ptc Therapeutics, Inc. 500 Warren Corporate Center Drive Warren NJ 07059 | Exec. Vp And Clo | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-03-12 | 13,126 | $33.02 | 117,027 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-03-12 | 13,126 | $53.31 | 103,901 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2025-03-12 | 2,395 | $33.02 | 106,296 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-03-12 | 2,395 | $53.23 | 103,901 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-12 | 13,126 | $0.00 | 13,126 | $33.02 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-12 | 2,395 | $0.00 | 2,395 | $33.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2029-01-21 | No | 4 | M | Direct | |
0 | 2029-01-21 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Currently exercisable.